Recordati (RECI)

Milan
Currency in EUR
48.36
-0.14(-0.29%)
Closed·
RECI Scorecard
Full Analysis
Has raised its dividend for 12 consecutive years
Fair Value
Day's Range
47.7848.44
52 wk Range
43.9860.95
Key Statistics
Edit
Prev. Close
48.5
Open
48.18
Day's Range
47.78-48.44
52 wk Range
43.98-60.95
Volume
251.52K
Average Volume (3m)
444.91K
1-Year Change
-3.01%
Book Value / Share
9.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RECI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
58.39
Upside
+20.74%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth
Show more

Recordati Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fortivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, a throat spray; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; REC 0559 for neurotrophic keratitis; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. Recordati Industria Chimica e Farmaceutica S.p.A. was founded in 1926 and is headquartered in Milan, Italy.

Employees
4539
Market
Italy

Compare RECI to Peers and Sector

Metrics to compare
RECI
Peers
Sector
Relationship
P/E Ratio
24.0x17.4x−0.5x
PEG Ratio
3.400.170.00
Price/Book
5.3x1.8x2.6x
Price / LTM Sales
4.3x2.1x2.9x
Upside (Analyst Target)
12.1%27.8%66.3%
Fair Value Upside
Unlock15.1%10.2%Unlock

Analyst Ratings

4 Buy
5 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 58.39
(+20.74% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.02%
Dividend Yield
2.63%
Industry Median 2.13%
Annualised payout
1.27
Paid unevenly
5-Years Growth
+4.90%
Growth Streak

Earnings

Latest Release
Feb 12, 2025
EPS / Forecast
-- / --
Revenue / Forecast
598.80M / 543.44M
EPS Revisions
Last 90 days

People Also Watch

17.540
ERG
-0.62%
19.18
LTMC
-0.05%
13.460
IVG
-2.00%
97.92
DIAS
-0.20%

FAQ

What Is the Recordati (RECI) Stock Price Today?

The Recordati stock price today is 48.36

What Stock Exchange Does Recordati Trade On?

Recordati is listed and trades on the Milan stock exchange.

What Is the Stock Symbol for Recordati?

The stock symbol for Recordati is "RECI."

Does Recordati Pay Dividends? What’s The Current Dividend Yield?

The Recordati dividend yield is 2.63%.

What Is the Recordati Market Cap?

As of today, Recordati market cap is 9.98B.

What is Recordati Earnings Per Share?

The Recordati EPS is 2.02.

What Is the Next Recordati Earnings Date?

Recordati will release its next earnings report on 07 May 2025.

From a Technical Analysis Perspective, Is RECI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.